Centiva Capital, LP Glaukos Corp Transaction History

Centiva Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$45.44 - $71.21 $154,450 - $242,042	3,399 Added 79.38%	7,681 $546,000
Q1 2023 May 15, 2023	BUY	$43.88 - $52.48 $187,894 - $224,719	4,282 New	4,282 $214,000
Q4 2021 Feb 14, 2022	SELL	$40.27 - $56.99 $203,081 - $287,400	-5,043 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$47.43 - $84.23 $239,189 - $424,771	5,043 New	5,043 $243,000

345

46.7M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.63B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.